Delivery Order SPE2DB22D2206-SPE2DB25FFZ82

Award Date 3/7/25
Potential Completion Date 3/28/25
Potential Value $1.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,659.62 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract has a completion date of January 3, 2025 and was awarded on December 11, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $38,865.20 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a critical medical product. The contract has an ultimate completion date of December 26, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $9,391.75 Delivery Order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a Firm Fixed Price Delivery Order to provide HYPERRAB 300 UNIT/ML VIAL 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $13,494.72 with a completion date of July 15, 2024, is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order (SPE2DB24D2205|SPE2DB25FDTRK) valued at $9,391.75 for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a specialty pharmaceutical product. The award was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 26, 2024. The contract is a firm fixed-price arrangement and does not have any set-aside designations, indicating open competition....
This federal contract award, with a total ceiling value of $7,513.40, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a critical pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the supply...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,744.80, is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML medical products. The award is a Firm Fixed Price Delivery Order with a completion date of February 19, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,155.12 Firm Fixed Price Delivery Order covers the supply of HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product, with a period of performance through January 22, 2025. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, is a $37,567.00 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued up to $999,999,999.00 through December 31,...
This federal contract award to AmerisourceBergen Drug Corp (a major pharmaceutical distributor) was issued by the Defense Logistics Agency (DLA) under an Indefinite Delivery Contract (IDC) for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML. The contract has a total ceiling value of $14,209.90 and a period of performance through February 28, 2025. The award is not designated as a set-aside contract. In addition to this specific delivery order, AmerisourceBergen holds a larger $999,999,999 IDC with...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FFZ82
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp is a Delivery Order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award, valued at $1,790.80, is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of March 28, 2025 and is a Firm Fixed Price arrangement. This award is part of Amerisourcebergen's larger $999,999,999 IDC with the DLA, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems.

Generated 6/6/25, 9:55 AM